Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) EBITDA: 2021-2025

Historic EBITDA for Kiniksa Pharmaceuticals International (KNSA) over the last 5 years, with Sep 2025 value amounting to $18.3 million.

  • Kiniksa Pharmaceuticals International's EBITDA rose 245.45% to $18.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $35.8 million, marking a year-over-year increase of 493.10%. This contributed to the annual value of -$43.4 million for FY2024, which is 408.71% down from last year.
  • According to the latest figures from Q3 2025, Kiniksa Pharmaceuticals International's EBITDA is $18.3 million, which was up 2.17% from $17.9 million recorded in Q2 2025.
  • Over the past 5 years, Kiniksa Pharmaceuticals International's EBITDA peaked at $224.1 million during Q3 2022, and registered a low of -$49.5 million during Q1 2021.
  • Moreover, its 3-year median value for EBITDA was -$4.0 million (2024), whereas its average is $1.4 million.
  • In the last 5 years, Kiniksa Pharmaceuticals International's EBITDA soared by 832.01% in 2022 and then plummeted by 135.69% in 2024.
  • Kiniksa Pharmaceuticals International's EBITDA (Quarterly) stood at -$36.4 million in 2021, then soared by 112.58% to $4.6 million in 2022, then skyrocketed by 451.78% to $25.2 million in 2023, then plummeted by 135.69% to -$9.0 million in 2024, then soared by 245.45% to $18.3 million in 2025.
  • Its EBITDA was $18.3 million in Q3 2025, compared to $17.9 million in Q2 2025 and $8.5 million in Q1 2025.